Brokerage firm Barclays Maintains its rating on Bruker Corporation(NASDAQ:BRKR). In a research note issued to the investors, the brokerage major Lowers the price-target to $30.00 per share. The shares have been rated Overweight. The rating by Barclays was issued on Aug 3, 2016.
In a different note, On Aug 3, 2016, Wells Fargo said it Downgrades its rating on Bruker Corporation. The shares have been rated ‘Market Perform’ by the firm. On Aug 3, 2016, Janney Capital said it Upgrades its rating on Bruker Corporation. The shares have been rated ‘Buy’ by the firm. On Jul 22, 2016, BTIG Research said it Assumes its rating on Bruker Corporation. The shares have been rated ‘Neutral’ by the firm.
Bruker Corporation (BRKR) shares turned negative on Fridays trading session with the shares closing down -0.02 points or -0.09% at a volume of 6,78,331. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $22.47. The peak price level was also seen at $22.47 while the days lowest was $22.16. Finally the shares closed at $22.31. The 52-week high of the shares is $29.85 while the 52-week low is $15.778. According to the latest information available, the market cap of the company is $3,604 M.
Bruker Corporation(BRKR) last announced its earnings results on Aug 2, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $371.70M. Analysts had an estimated revenue of $409.57M. Earnings per share were $0.20. Analysts had estimated an EPS of $0.20.
Several Insider Transactions has been reported to the SEC. On Jun 15, 2016, Frank H Laukien (CEO) purchased 4,174 shares at $23.95 per share price.Also, On Jun 7, 2016, Joerg C Laukien (director 10% owner) sold 2,000,000 shares at $25.65 per share price.On May 11, 2016, Brenda J Furlong (director) sold 22,600 shares at $27.43 per share price, according to the Form-4 filing with the securities and exchange commission.
Bruker Corporation is a designer and manufacturer of life science and materials research systems and associated products that address the needs of a range of customers in life science research pharmaceuticals applied markets nanotechnology cell biology clinical research microbiology and in-vitro diagnostics. The Company operates through two segments: Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). BSI is organized into three operating segments: the Bruker BioSpin Group the Bruker CALID Group and the Bruker Nano Group. BEST designs manufactures and distributes superconducting materials. The company maintains technical and manufacturing centers in Europe and North America and it has sales offices located throughout the world.